« Return to News | Clinical Intelligence

Selexys Pharmaceuticals concludes phase I study in sickle cell disease

Thursday, June 14, 2012 11:54 AM

Selexys Pharmaceuticals, a privately held biopharmaceutical company based in Oklahoma City, Okla., has completed a phase I clinical study of its lead compound SelG1, an antibody specific for the pro-inflammatory cell adhesion molecule P-selectin.

The placebo-controlled, double-blind, ascending single dose and multiple dose study of SelG1 enrolled 27 healthy subjects. The study evaluated the safety and pharmacology of SelG1 to support its advancement into a phase II clinical trial in patients with sickle cell disease.

SelG1 appeared to be safe and well tolerated, with no serious adverse events reported in any subjects. There was no observed immune response to SelG1 during the study. Analysis of SelG1 pharmacokinetic and pharmacodynamic data demonstrated a serum half-life of approximately two weeks and complete blockade of P-selectin activity in all patients for at least one month following a single intravenous dose.

"This phase I study represents a major step in understanding the potential of SelG1 to address the unmet medical need in sickle cell disease and other indications," said Dr. Scott Rollins, president and CEO of Selexys.

In 2008, Selexys received orphan-drug designation for SelG1 from the FDAn Office of Orphan Products Development for the treatment of vasoocclusive crisis, a severe and painful complication of sickle cell disease.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.